A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Saved in:
| Title: | A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. |
|---|---|
| Authors: | Mooradian, Meghan J.1,2, Reuben, Alexandre3, Prieto, Peter A.3, Hazar-Rethinam, Mehlika1,2, Frederick, Dennie T.1, Nadres, Brandon1,2, Piris, Adriano2,4, Juneja, Vikram5,6,7, Cooper, Zachary A.3, Sharpe, Arlene H.2,5,7, Corcoran, Ryan B.1,2, Flaherty, Keith T.1,2, Lawrence, Donald P.1,2, Wargo, Jennifer A.3, Sullivan, Ryan J.1,2,8 rsullivan7@partners.org |
| Source: | OncoImmunology. 2018, Vol. 7 Issue 5, p1-1. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
